Eko Murmur Analysis Software (EMAS) vs Fetal EchoScan
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A, Eko Murmur Analysis Software, is designed for post-natal detection and differentiation of heart murmurs in adult and pediatric patients using digital stethoscopes. In contrast, Tool B, Fetal EchoScan, focuses on prenatal detection of congenital heart defects through AI-powered ultrasound screening. While both are cardiology AI tools, their distinct patient populations and diagnostic modalities make them complementary rather than direct competitors.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Eko Murmur Analysis Software (EMAS) is an FDA-cleared AI tool designed for the post-natal detection and differentiation of heart murmurs in adult and pediatric patients, providing clinical decision support for early detection of heart and lung disease. In contrast, Fetal EchoScan is an FDA-cleared AI-powered ultrasound screening software that assists clinicians in the prenatal detection of congenital heart defects in fetuses.
EMAS integrates with Eko digital stethoscopes (CORE 500, DUO, CORE) and is accessed via a mobile application with wireless Bluetooth connectivity for recording, playback, and sharing. Fetal EchoScan is a cloud-based software-only device that integrates seamlessly with existing ultrasound machines and reporting solutions, utilizing DICOM compatibility and a cart-side tablet display for real-time AI analysis and alerts.
EMAS offers FDA-cleared AI for murmur detection, analyzing heart sound (PCG) and optional ECG data to differentiate innocent and structural heart murmurs, and provides clinical decision support. Fetal EchoScan provides AI-driven support for prenatal ultrasound examinations, offering automated detection of congenital heart defects (CHDs), real-time guidance, and feedback to ensure exam completeness and standardization of fetal heart assessments.
EMAS provides clinical decision support to improve the accuracy and efficiency of screening for heart valve disease and helps uncover early valvular heart disease. Fetal EchoScan aims to optimize workflow and achieve faster reading times for clinicians, while also reducing false-negative and false-positive errors in congenital heart defect detection through real-time guidance and standardization.
More Comparisons
Backers
Who funded each tool's parent company.